Epidemiology and Treatment of MIS-C

Explore the latest insights on Multisystem Inflammatory Syndrome in Children (MIS-C) related to COVID-19 in this World Shared Practice Forum video from the International PICU COVID-19 Collaborative. Gain valuable knowledge from Dr. Michael Levin's discussion on new MIS-C literature and participate in an expert panel discussion with members of the American College of Rheumatology Task Force on MIS-C. Learn about global trends in COVID-19 treatments, understand the nuances of MIS-C based on recent research, and discover current clinical practice guidance for managing pediatric patients with MIS-C. Delve into topics such as distinguishing MIS-C from Kawasaki disease and other inflammatory conditions, the relationship between MIS-C and SARS-CoV-2, immunomodulatory treatment strategies, anticoagulation decisions, and management considerations in resource-limited environments. Enhance your understanding of this critical pediatric condition and its treatment approaches through this comprehensive 47-minute presentation.

Intro
HOW does MIS-C differ from Kawasaki disease, KD, shock, and TSS
Can MIS-C be distinguished from other infectious and inflammatory diseases ?
Clinical features conclusions
What is the relationship of MISC to COVID 19 and SARS Cov2?
Possible mechanism for acquired immunity mediating inflammation and organ damage ??
When Should Immunomodulatory Treatments Be Started for MIS-C?
Do All MIS-C Patients Need Treatment?
Treatment For MIS-C Derived From Kawasaki Disease Management
Which Patients Need Anticoagulation?
Should Therapy Change If Enlarging Coronary Aneurysm?
How Should Management Change in Resource-limited Environments?
Does Sequence of Treatment Matter?
How Can Biomarkers (D-dimer, fibrinogen) Help Make Anticoagulation Decisions?